Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaomi Nangaku

Showing results (1-10 of 841) with videos related to

Pageof 85
Sort By:
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|July 16, 2013
[Progressive renal diseases: recent advances in diagnosis and treatments. Topics: III. Recent topics; 1. Future perspectives of kidney disease]Masaomi Nangaku
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2017
Pathogenesis and treatment of anemia in chronic kidney diseaseMasaomi Nangaku
Nephrology (Carlton, Vic.)|August 3, 2023
Global perspective of kidney diseases: Challenges and changesMasaomi Nangaku
Nephron. Experimental Nephrology|September 14, 2004
Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failureMasaomi Nangaku
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|April 10, 2010
[Mechanism of the development of renal anemia and its treatment]Masaomi Nangaku
Advances in Experimental Medicine and Biology|February 21, 2009
Novel therapeutic approach targeting the HIF-HRE system in the kidneyMasaomi Nangaku
Kidney International|August 31, 2013
Tissue protection by erythropoietin: new findings in a moving fieldMasaomi Nangaku
Kidney International|October 17, 2020
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKDMasaomi Nangaku
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|June 15, 2012
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 7. Renal anemia]Masaomi Nangaku
Kidney International|October 31, 2020
Metformin-to use or not to use . . . is that the question?Masaomi Nangaku
Pageof 85

Showing results (1-10 of 841) with videos related to

Sort By:
Pageof 85
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|July 16, 2013
[Progressive renal diseases: recent advances in diagnosis and treatments. Topics: III. Recent topics; 1. Future perspectives of kidney disease]Masaomi Nangaku
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2017
Pathogenesis and treatment of anemia in chronic kidney diseaseMasaomi Nangaku
Nephrology (Carlton, Vic.)|August 3, 2023
Global perspective of kidney diseases: Challenges and changesMasaomi Nangaku
Nephron. Experimental Nephrology|September 14, 2004
Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failureMasaomi Nangaku
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|April 10, 2010
[Mechanism of the development of renal anemia and its treatment]Masaomi Nangaku
Advances in Experimental Medicine and Biology|February 21, 2009
Novel therapeutic approach targeting the HIF-HRE system in the kidneyMasaomi Nangaku
Kidney International|August 31, 2013
Tissue protection by erythropoietin: new findings in a moving fieldMasaomi Nangaku
Kidney International|October 17, 2020
More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKDMasaomi Nangaku
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|June 15, 2012
[Chronic kidney disease (CKD)--recent progress. Topics: VI. Chronic kidney disease (CKD) and associated disorders; 7. Renal anemia]Masaomi Nangaku
Kidney International|October 31, 2020
Metformin-to use or not to use . . . is that the question?Masaomi Nangaku
Pageof 85